ReviewCancers2019
Targeting Programmed
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Review
- Microbial crosstalk along the oral-gut axis: organ-specific oncogenic adaptations of Porphyromonas gingivalis and Fusobacterium nucleatum.Neoplasia (New York, N.Y.) · 2026Review
- Microbial oncogenesis: the impact of Fusobacterium nucleatum on oral cancer pathways.Medical oncology (Northwood, London, England) · 2025Review
- Targeting Fusobacterium nucleatum in colorectal cancer: therapeutic strategies and future directions.Infectious agents and cancer · 2025Review
- Fusobacterium nucleatum and non-coding RNAs: orchestrating oncogenic pathways in colorectal cancer.Gut pathogens · 2025Review
- Bacteria and Carcinogenesis and the Management of Cancer: A Narrative Review.Pathogens (Basel, Switzerland) · 2025Review
- Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance.Cancer biology & therapy · 2024Review
- Article
- Oral Pathobiont-Derived Outer Membrane Vesicles in the Oral-Gut Axis.International journal of molecular sciences · 2024Review
- Intratumoral microbiota in colorectal cancer: focus on specific distribution and potential mechanisms.Cell communication and signaling : CCS · 2024Review
- Fusobacterium nucleatum carcinogenesis and drug delivery interventions.Advanced drug delivery reviews · 2024Review
- Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Cell Surface Fibroblast Activation Protein-2 (Fap2) ofVaccines · 2023Article
- Fn-Dps, a novel virulence factor of Fusobacterium nucleatum, disrupts erythrocytes and promotes metastasis in colorectal cancer.PLoS pathogens · 2023Article
- A Review of the Pharmacological Potential ofCells · 2022Review
- The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development.BMC microbiology · 2022Review
- The microbiome, gastrointestinal cancer, and immunotherapy.Journal of gastroenterology and hepatology · 2022Review
- Review
- Pathogenic Mechanisms ofFrontiers in oral health · 2022Review
- Profiling of Antifungal Activities and In Silico Studies of Natural Polyphenols from Some Plants.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
Colorectal patients generally have the maximum counts of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.